
Actinium Pharmaceuticals fell 23.4% from $1.37 to $1.05, behind the S&P 500's +3.2%. Its worst day was Nov 18 (−20.0%), and its low came Aug 5 at $0.75.
Nov 24, 2025 – Nov 20, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
Actinium Pharmaceuticals closed at its highest level of the year, 23.4% above where the year started.
+6.3% · S&P 500 +0.9%
EPS of $-0.19 beat the $-0.22 estimate on $0.00 revenue.
Story events cover the past 12 months · Times ET
+0.5% · S&P 500 +2.9%
Actinium Pharmaceuticals shares rose 14.5%, while the S&P 500 rose 0.8%.
+14.5% · S&P 500 +0.8%
EPS of $-0.18 beat the $-0.22 estimate on $0.00 revenue.
+2.3% · S&P 500 +0.2%
EPS of $0.89 beat the $-0.20 estimate on $35.0M revenue.
−3.4% · S&P 500 0.0%
Actinium Pharmaceuticals shares rose 19.4%, while the S&P 500 fell 0.5%.
+19.4%, the year's best day · S&P 500 −0.5%
First-in-human Phase 1 presentation to feature ATNM-400 clinical data in metastatic castration-resistant prostate cancer, advancing a differentiated approach beyond PSMAPreclinical presentation to feature ATNM-400
+16.8% · S&P 500 +0.4%
EPS of $-0.19 beat the $-0.25 estimate on $0.00 revenue.
−9.4% · S&P 500 −1.0%
Where it ended: a close of $1.05 on Nov 20, 2026.
Nothing in the past 12 months.
All ATNM analyst actionsNothing in the past 12 months.
All ATNM dividend historyReplay the year: the line draws itself and stops at each of the 8 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for ATNM and SPY from Benzinga historical bars. Not investment advice.